You are now leaving the Hypermunes.com Web site.

Links to external, non-Talecris Biotherapeutics Internet sites are provided as a courtesy; however, Talecris Biotherapeutics is not responsible for the availability or the content of such Web sites.

Please see our General Conditions of Use for more information.

OK     CANCEL
 
https://www.novartisvaccinesdirect.com/Rabavert/RabavertAbout

HyperRAB S/D [Rabies Immune Globulin (Human)]
postexposure prophylaxis for rabies

HyperRAB S/D Postexposure Prophylaxis for Rabies

Rabies Quick Facts

  • Up to 39,000 persons come in contact with potentially rabid animals and receive rabies postexposure prophylaxis each year1
  • According to the Centers for Disease Control and Prevention (CDC), the most common sources of human rabies in the USA are bats2
  • Each year rabies kills more than 55,000 people worldwide3
  • Once the signs and symptoms of rabies start to appear, there is no treatment and the disease is almost always fatal3

HyperRAB S/D Quick Facts

  • HyperRAB S/D is mercury (thimerosal) free and latex free4
  • Only HyperRAB S/D has FDA labeling for removal of pathogenic prions that may cause TSEs* in humans
    • HyperRAB S/D is made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products
  • HyperRAB S/D provides tamper-evident packaging
  • Convenient prefilled vials for single-use IM injection only4

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


HyperRAB S/D IMPORTANT SAFETY INFORMATION

Rabies vaccine and HyperRAB S/D should be given to all persons suspected of exposure to rabies with one exception: persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

HyperRAB S/D (Rabies Immune Globulin [Human]) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.

The attending physician who wishes to administer HyperRAB S/D to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

Soreness at the site of injection and mild temperature elevations may be observed at times. Sensitization to repeated injections has occurred occasionally in immunoglobulin-deficient patients. Angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock have rarely been reported after intramuscular injection so that a causal relationship between immunoglobulin and these reactions is not clear.

Administration of live virus vaccines (e.g., MMR) should be deferred for approximately 3 months after rabies immune globulin (human) administration.

HyperRAB S/D is made from human plasma. Product made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.


RabAvert IMPORTANT SAFETY INFORMATION

RabAvert (rabies vaccine) is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups.

Anaphylaxis, encephalitis including death, meningitis, neuroparalytic events such as encephalitis, transient paralysis, Guillain-Barré Syndrome, myelitis, and retrobulbar neuritis; and multiple sclerosis have been reported to be temporally associated with the use of RabAvert.

The most commonly occurring adverse reactions are injection site reactions, such as injection site erythema, induration and pain; flu-like symptoms; arthralgia; dizziness; lymphadenopathy; nausea; and rash.

History of anaphylaxis to the vaccine or any of the vaccine components constitutes a contraindication to preexposure vaccination with this vaccine. In the case of postexposure prophylaxis, if an alternative product is not available, vaccination should proceed with caution and close observation. A patient’s risk of acquiring rabies must be carefully considered before discontinuing vaccination.

For full Prescribing Information, click here.

*Human TSEs (transmissible spongiform encephalopathies) are a group of neurodegenerative diseases related to mad cow disease.

References:

  1. Manning SE, Rupprecht CE, Fishbein D, et al; Centers for Disease Control and Prevention. Human rabies prevention—US, 2008: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR-03):1-38.

  2. Centers for Disease Control and Prevention. Questions and answers about rabies, bats and summer camps. http://www.cdc.gov/rabies/qanda/bats_camps.html. Accessed June 17, 2009.

  3. World Health Organization. Rabies key facts. http://who.int/mediacentre/factsheets/fs099/en. Accessed June 17, 2009.

  4. HyperRAB S/D [package insert]. Research Triangle Park, NC: Talecris Biotherapeutics; 2008.

RabAvert is a registered trademark of Novartis Vaccines and Diagnostics Inc.